The egypt diabetes care drugs and devices market size is expected to grow from USD 789.12 million in 2025 to USD 807.96 million in 2026 and is forecast to reach USD 919.56 million by 2031 at 2.62% CAGR over 2026-2031. This report is Segmented by Device Category (Drugs [Insulin, Oral Anti-Diabetic Drugs, Adjunctive Therapies], Glucose Monitoring Devices [SMBG, CGM], Insulin Delivery Devices, Other Devices), Diabetes Type (Type 1, Type 2, Gestational & Others), End User (Hospital Pharmacies, Retail Pharmacies, Online Sales, Other End Users). The Market Forecasts are Provided in Value (USD) and Volume (Units).
Drugs will keep the lion’s share in the Egypt diabetes drugs and devices market through 2031 because every Type 1 and one-third of Type 2 patients depend on insulin. Yet value migrates toward delivery hardware as local pen fills drive down prices and as hospital tenders start to bundle drug+device. Meanwhile, insulin biosimilars push average insulin price per vial down, but higher treated volumes offset margin contraction.
Egypt Diabetes Care Drugs And Devices Market Trends and Insights
Rising Diabetes Prevalence & Incidence
Age-standardized prevalence reached 22.4% in 2024, equal to 13.2 million adults, yet 8.2 million remain undiagnosed. Urban governorates screen more aggressively, leaving rural Upper Egypt lagging by up to 20 percentage points. Each newly diagnosed patient adds approximately USD 235 to annual drug and device spend, so UHIS expansion converts public health need into commercial volume. Diabetes expenditure hit USD 3.1 billion in 2024, underscoring budget pressure but also revealing scope for scale.Government UHIS Rollout & National Screening Drives
UHIS, backed by EGP 166 billion (USD 5.4 billion), completed Phase 1 by 2024 and is now expanding into Upper Egypt, adding 8 million beneficiaries by 2028. Protocols require annual screening for adults over 40, creating a sustained funnel of newly diagnosed users for glucose meters, CGM sensors, and generic metformin. A USD 400 million World Bank loan earmarks one-third of the funds for non-communicable disease equipment, accelerating procurement cycles.High Out-of-Pocket Costs & Limited Device Reimbursement
Out-of-pocket spending reached 60% of total health expenditure in 2024. A FreeStyle Libre sensor costs 3.2 days of wages for the lowest-paid worker, versus 0.5 days for a month of metformin. UHIS covers essential medicines but excludes CGM and GLP-1 drugs, creating a two-tier system in which low-income patients rely on generics and basic meters.Other drivers and restraints analyzed in the detailed report include:
- Local Insulin-Manufacturing Push Securing Supply
- Accelerating Adoption of CGM & Smart Insulin Delivery Tech
- FX-Driven Input-Cost Inflation for Imported Components
Segment Analysis
Drugs generated 61.83% of Egypt diabetes drugs and devices market revenue in 2025, and insulin alone contributed nearly half of that value. Within drugs, basal analogs such as glargine and degludec outsell NPH in urban centers, yet low-cost NPH still anchors rural formularies. Oral agents continue to treat the Type 2 majority, though SGLT-2 and GLP-1 uptake stays low because of cost and prescriber habits. Insulin-delivery devices represent the fastest-growing segment, with a 3.79% CAGR, moving users from vial-and-syringe to smart pens that store dose data. CGM shipments grow from a low installed base, while commodity lancets and strips support daily adherence. ISO 15197 compliance keeps no-name meters out, consolidating share with Roche, Abbott, and Sinocare.Drugs will keep the lion’s share in the Egypt diabetes drugs and devices market through 2031 because every Type 1 and one-third of Type 2 patients depend on insulin. Yet value migrates toward delivery hardware as local pen fills drive down prices and as hospital tenders start to bundle drug+device. Meanwhile, insulin biosimilars push average insulin price per vial down, but higher treated volumes offset margin contraction.
Complete Report Scope:
- By Device Category
- Drugs
- Insulin
- Oral Anti-Diabetic Drugs
- Adjunctive Therapies
- Glucose Monitoring Devices
- Self-Monitoring Blood Glucose (SMBG) Devices
- Continuous Glucose Monitoring (CGM) Devices
- Insulin Delivery Devices
- Other Diabetes-Care Devices
- Drugs
- By Diabetes Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational & Others
- By End User
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
- Other End Users
List of Companies Covered in this Report:
- Abbott Laboratories
- AstraZeneca
- B. Braun
- Beckton Dickinson
- Dexcom
- Eli Lilly and Company
- Insulet
- Medtronic
- MicroPort
- Novo Nordisk
- Omnipod
- Roche
- Sanofi
- Senseonics Holdings
- Sinocare
- Tandem Diabetes Care
- Ypsomed
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value & Volume)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Diabetes Care
- Astrazeneca
- B. Braun Melsungen AG
- Becton Dickinson and Company
- Dexcom Inc.
- Eli Lilly and Company
- Insulet Corporation
- Medtronic
- MicroPort Scientific
- Novo Nordisk A/S
- Omnipod
- Roche Diabetes Care
- Sanofi S.A.
- Senseonics Holdings
- Sinocare Inc.
- Tandem Diabetes Care
- Ypsomed AG
